Fig. 9. MYCN expression is a determinant of indisulam sensitivity in neuroblastoma.

a, b Dose–response curve in six neuroblastoma lines, three without and three with MYCN amplification of indisulam (a) or E7820 (b). Cell survival was determined after 72 h with Cell-Titre Glo (n = 3 independent experiments). c Western blot for N-Myc and GAPDH on six neuroblastoma lines. d Dose–response curve in Tet21 MYCN ON or MYCN OFF (treated with 1 µg ml⁻¹ doxycycline) of indisulam. Cell survival was determined after 72 h with Cell-Titre Glo (n = 3 independent experiments). Western blot of n-Myc and GAPDH. Blot is representative of n = 3 independent experiments. e 50% Surviving Fraction (SF50) of neuroblastoma cells (dots represent mean SF50 of n = 3 independent experiments) treated with indisulam (n = 8 cell lines, 3 MYCNamp, 3 no MYCNamp, 2 Tet21) or E7820 (n = 6 cell lines, 3 MYCNamp, 3 no MYCNamp). Data are presented as mean ± SD (a, b, d) or SEM (e). Statistical analysis in e was determined by a two-tailed unpaired t-test. Source data is provided as a Source Data File.